Stryker Co. (NYSE:SYK) Stock Holdings Lowered by GAM Holding AG

GAM Holding AG cut its position in Stryker Co. (NYSE:SYK) by 8.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,900 shares of the medical technology company’s stock after selling 887 shares during the quarter. GAM Holding AG’s holdings in Stryker were worth $3,564,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stratos Wealth Advisors LLC boosted its stake in Stryker by 3.4% during the third quarter. Stratos Wealth Advisors LLC now owns 4,177 shares of the medical technology company’s stock valued at $1,509,000 after buying an additional 139 shares in the last quarter. Capital Investment Advisors LLC lifted its holdings in Stryker by 102.5% in the 3rd quarter. Capital Investment Advisors LLC now owns 1,855 shares of the medical technology company’s stock valued at $670,000 after acquiring an additional 939 shares during the last quarter. New Century Financial Group LLC boosted its position in shares of Stryker by 7.5% during the 3rd quarter. New Century Financial Group LLC now owns 858 shares of the medical technology company’s stock valued at $310,000 after purchasing an additional 60 shares in the last quarter. Godsey & Gibb Inc. grew its stake in shares of Stryker by 0.6% in the 3rd quarter. Godsey & Gibb Inc. now owns 67,260 shares of the medical technology company’s stock worth $24,298,000 after purchasing an additional 402 shares during the last quarter. Finally, Brown Lisle Cummings Inc. raised its holdings in shares of Stryker by 22.5% in the 3rd quarter. Brown Lisle Cummings Inc. now owns 6,386 shares of the medical technology company’s stock worth $2,307,000 after purchasing an additional 1,175 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 0.9 %

Stryker stock opened at $385.05 on Tuesday. The firm’s fifty day simple moving average is $377.31 and its 200-day simple moving average is $367.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a market capitalization of $146.79 billion, a P/E ratio of 49.62, a P/E/G ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm earned $3.46 EPS. Sell-side analysts forecast that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is 43.30%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. UBS Group raised their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Truist Financial boosted their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, Robert W. Baird boosted their price objective on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $420.68.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.